MILESTONE: strona spółki
4.01.2021, 15:22
MMD The Entrée into the Nationally Recognized University of Texas Medical Branch at Galveston with its CompuFlo Disposables
The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”) today announced that as per a purchase order the Company received in late 2020, the Issuer has begun selling CompuFlo® disposables to the University of Texas Medical Branch at Galveston (UTMB), an institution of the University of Texas System and agency of the State of Texas. UTMB is a major academic health sciences center of global influence, with medical, nursing, health professions and graduate biomedical schools; a world-renowned research enterprise; and a growing, comprehensive health system with hospitals on four campuses.
The clinical and safety benefits of the CompuFlo Epidural / CathCheck Systems are backed by extensive published clinical data demonstrating significant reductions in epidural punctures, as well as complication rates, and contributes to a significant savings of time on the part of anesthesiologists. Moreover, the CompuFlo instrument has the potential to significantly reduce costs associated with morbidity, providing a direct economic benefit to healthcare institutions. Similarly, the CathCheck technology has the potential to transform the monitoring of catheter placement following an epidural procedure by confirming the placement of a catheter within 2 minutes, versus 20-40 minutes using conventional methods. The Board of Directors of the Issuer is encouraged to announce this decision by UTMB, a leading regional hospital and medical teaching institute. The Board of Directors of the Company believes this will be the first of many such hospitals to come, and the Issuer commends UTMB on their commitment to the health and safety of their patients. The Board of Directors of the Issuer believes the use of the CompuFlo provides a level of safety and efficiency not otherwise available for patients. Furthermore, as a major teaching institute, The Board of Directors of the Company believes UTMB will have the opportunity to shorten the training time and increase efficiencies for residents performing epidural procedures through the use of the instrument and disposables. Additionally, the use of CathCheck provides physicians the opportunity to monitor catheter placement after a procedure. Moreover, the use of the instruments and disposables provide a significant economic benefit to the institution. The Board of Directors of the Issuer believes this is just the start of a steady commercial rollout in the weeks and months to come. Overall, the response from both hospitals and physicians has been very positive and the Company is in a number of similar trials across the country that The Board of Directors of the Issuer believes and expects will convert to commercial orders. The Company has been working closely with Dr. Rovnat Babazade, MD and Assistant Professor University of Texas Medical Branch, Galveston, and The Board of Directors of the Issuer is grateful for his support. Dr. Babazade previously conducted a study with the aim of evaluating the cost-effectiveness of the CompuFlo® Epidural System with DPS Dynamic Pressure Sensing technology® versus the traditional loss of resistance technique within the labor and delivery setting in medical centers. The results of the study suggest that when compared to the traditional LOR technique, real-time pressure sensing technology costs about 504 dollars less per hospital stay on average. The Board of Directors of the Company appreciates the decision of Dr. Babazade and his team to purchase its consumables following approval by the Value Analysis Team at UTMB. This decision by a leading U.S. medical center further reinforces the confidence in the outlook for both CathCheck and CompuFlo, as well as the significant market opportunity as the Company strives to become the new standard of care in epidural procedures.
The clinical and safety benefits of the CompuFlo Epidural / CathCheck Systems are backed by extensive published clinical data demonstrating significant reductions in epidural punctures, as well as complication rates, and contributes to a significant savings of time on the part of anesthesiologists. Moreover, the CompuFlo instrument has the potential to significantly reduce costs associated with morbidity, providing a direct economic benefit to healthcare institutions. Similarly, the CathCheck technology has the potential to transform the monitoring of catheter placement following an epidural procedure by confirming the placement of a catheter within 2 minutes, versus 20-40 minutes using conventional methods. The Board of Directors of the Issuer is encouraged to announce this decision by UTMB, a leading regional hospital and medical teaching institute. The Board of Directors of the Company believes this will be the first of many such hospitals to come, and the Issuer commends UTMB on their commitment to the health and safety of their patients. The Board of Directors of the Issuer believes the use of the CompuFlo provides a level of safety and efficiency not otherwise available for patients. Furthermore, as a major teaching institute, The Board of Directors of the Company believes UTMB will have the opportunity to shorten the training time and increase efficiencies for residents performing epidural procedures through the use of the instrument and disposables. Additionally, the use of CathCheck provides physicians the opportunity to monitor catheter placement after a procedure. Moreover, the use of the instruments and disposables provide a significant economic benefit to the institution. The Board of Directors of the Issuer believes this is just the start of a steady commercial rollout in the weeks and months to come. Overall, the response from both hospitals and physicians has been very positive and the Company is in a number of similar trials across the country that The Board of Directors of the Issuer believes and expects will convert to commercial orders. The Company has been working closely with Dr. Rovnat Babazade, MD and Assistant Professor University of Texas Medical Branch, Galveston, and The Board of Directors of the Issuer is grateful for his support. Dr. Babazade previously conducted a study with the aim of evaluating the cost-effectiveness of the CompuFlo® Epidural System with DPS Dynamic Pressure Sensing technology® versus the traditional loss of resistance technique within the labor and delivery setting in medical centers. The results of the study suggest that when compared to the traditional LOR technique, real-time pressure sensing technology costs about 504 dollars less per hospital stay on average. The Board of Directors of the Company appreciates the decision of Dr. Babazade and his team to purchase its consumables following approval by the Value Analysis Team at UTMB. This decision by a leading U.S. medical center further reinforces the confidence in the outlook for both CathCheck and CompuFlo, as well as the significant market opportunity as the Company strives to become the new standard of care in epidural procedures.